{"DataElement":{"publicId":"7028298","version":"1","preferredName":"Endometrioid Stroma Sarcoma Histologic Grade","preferredDefinition":"The grade representing the extent of endometrioid stroma sarcoma in the body.","longName":"EDMTR_STRSARC_HX_GD","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"7027521","version":"1","preferredName":"Endometrioid Stromal Sarcoma Histologic Grade","preferredDefinition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma._The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","longName":"7027519v1.0:2427327v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"7027519","version":"1","preferredName":"Endometrioid Stromal Sarcoma","preferredDefinition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","longName":"C8973","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AF60BC-1C91-7610-E053-F662850A7319","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2427327","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05116195-EBA8-7341-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AF60BC-1C9F-7610-E053-F662850A7319","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7027522","version":"1","preferredName":"Endometrioid Stroma Sarcoma Histologic Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"7027522v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"With Sarcomatous Overgrowth","valueDescription":"Sarcomatous Component Present","ValueMeaning":{"publicId":"7027523","version":"1","preferredName":"Sarcomatous Component Present","longName":"7027523","preferredDefinition":"A histopathologic finding characterized by the presence of malignant cells of connective tissue origin in a tumor sample.  Examples of connective tissue cells that can undergo malignant transformation include smooth and skeletal muscle cells, adipose tissue cells, osteocytes, and chondrocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatous Component Present","conceptCode":"C54727","definition":"A histopathologic finding characterized by the presence of malignant cells of connective tissue origin in a tumor sample.  Examples of connective tissue cells that can undergo malignant transformation include smooth and skeletal muscle cells, adipose tissue cells, osteocytes, and chondrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AEABF5-ACEE-75F8-E053-F662850AED33","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95AEABF5-AD07-75F8-E053-F662850AED33","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Cannot Be Assessed","valueDescription":"Cannot Be Assessed","ValueMeaning":{"publicId":"2897789","version":"1","preferredName":"Cannot Be Assessed","longName":"2897789","preferredDefinition":"Aspects of the context prevent the evaluation needed to determine a value.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cannot Be Assessed","conceptCode":"C48657","definition":"Aspects of the context prevent the evaluation needed to determine a value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B943018-A5FF-1429-E040-BB89AD4312C2","latestVersionIndicator":"Yes","beginDate":"2009-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95AEABF5-AD1B-75F8-E053-F662850AED33","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"High Grade","valueDescription":"High Grade","ValueMeaning":{"publicId":"3288211","version":"1","preferredName":"High Grade","longName":"3288211","preferredDefinition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade","conceptCode":"C14158","definition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6DC488-B15F-8FD1-E040-BB89AD432EE0","latestVersionIndicator":"Yes","beginDate":"2011-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95AEABF5-AD25-75F8-E053-F662850AED33","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Low Grade","valueDescription":"Low Grade","ValueMeaning":{"publicId":"3288210","version":"1","preferredName":"Low Grade","longName":"3288210","preferredDefinition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6DC488-B13C-8FD1-E040-BB89AD432EE0","latestVersionIndicator":"Yes","beginDate":"2011-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95AEABF5-AD2F-75F8-E053-F662850AED33","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2453188","version":"1","preferredName":"Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0DDD1E7C-BBFA-66D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AEABF5-ACD4-75F8-E053-F662850AED33","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"7026248","version":"1","longName":"Endometrial","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Histologic grade","type":"Preferred Question Text","description":"Histologic grade","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95C4CF3D-A036-63FC-E053-F662850A8EA9","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-25","modifiedBy":"HARTLEYG","dateModified":"2019-11-07","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}